The 2014 rally was started by K tumor shrinkage report and the Merck Cubist deal which Absssi was compared. Prurisol was not thought of as a game changer either. So there’s definitely a chance B can propel the stock much higher with K still in waiting. I’m still leaning a complete sale over company build-out.
Market Data 
Markets 
AI
